⌘K

News Latest Analysis Investing Ideas Data Stories Crypto

Education Articles

Our education section provides in-depth guides and articles across a range of topics.

Investing Glossary

Our glossary is a great place to start if you’re new to the world of investing.

⌘K

Cardiol Therapeutics

pdf

About Cardiol Therapeutics Inc

Leadership at Cardiol Therapeutics

David Elsley, MBA

President and CEO
Dr. Guillermo Torre-Aminone, MD, PhD

Chairman
Jennifer M. Chao, BA

Director
Colin G. Stott, BSc (Hons)

Director

Latest Cardiol Therapeutics Press Releases

Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis

February 21, 2024

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

February 15, 2024

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

January 9, 2024

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis

November 1, 2023

Cardiol Therapeutics Announces Year-End 2022 Update on Operations

March 28, 2023

Latest Analysis

The United States Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland, USA.

Cardiol Therapeutics Receives Orphan Drug Designation for Pericarditis Treatment